Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors

被引：0
作者：
Edward Sausville
Patricia LoRusso
Michael Carducci
Judith Carter
Mary F. Quinn
Lisa Malburg
Nilofer Azad
David Cosgrove
Richard Knight
Peter Barker
Sonya Zabludoff
Felix Agbo
Patricia Oakes
Adrian Senderowicz
机构：
[1] University of Maryland,Marlene and Stewart Greenebaum Cancer Center
[2] Wayne State University School of Medicine,Karmanos Cancer Center
[3] Johns Hopkins Medical Institutions,Sidney Kimmel Comprehensive Cancer Center
[4] AstraZeneca,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2014年 / 73卷
关键词：
AZD7762; Chk1; Solid tumors; Phase I; Safety; Pharmacokinetics;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：539 / 549
页数：10
相关论文
共 50 条
  • [21] A phase I combination dose-escalation study of eribulin mesylate and gemcitabine in patients with advanced solid tumours: a study of the Princess Margaret Consortium
    Lheureux, S.
    Oza, A. M.
    Laurie, S. A.
    Halford, R.
    Jonker, D.
    Chen, E.
    Keller, D.
    Bourade, V.
    Wang, L.
    Doyle, L.
    Siu, L. L.
    Goel, R.
    BRITISH JOURNAL OF CANCER, 2015, 113 (11) : 1534 - 1540
  • [22] A phase I combination dose-escalation study of eribulin mesylate and gemcitabine in patients with advanced solid tumours: a study of the Princess Margaret Consortium
    S Lheureux
    A M Oza
    S A Laurie
    R Halford
    D Jonker
    E Chen
    D Keller
    V Bourade
    L Wang
    L Doyle
    L L Siu
    R Goel
    British Journal of Cancer, 2015, 113 : 1534 - 1540
  • [23] A Phase I study of pazopanib in combination with gemcitabine in patients with advanced solid tumors
    Plummer, Ruth
    Madi, Ayman
    Jeffels, Melinda
    Richly, Heike
    Nokay, Bahar
    Rubin, Stephen
    Ball, Howard A.
    Weller, Steve
    Botbyl, Jeffrey
    Gibson, Diana M.
    Scheulen, Max E.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 71 (01) : 93 - 101
  • [24] A Phase I study of pazopanib in combination with gemcitabine in patients with advanced solid tumors
    Ruth Plummer
    Ayman Madi
    Melinda Jeffels
    Heike Richly
    Bahar Nokay
    Stephen Rubin
    Howard A. Ball
    Steve Weller
    Jeffrey Botbyl
    Diana M. Gibson
    Max E. Scheulen
    Cancer Chemotherapy and Pharmacology, 2013, 71 : 93 - 101
  • [25] Phase I dose-escalation study of chiauranib, a novel angiogenic, mitotic, and chronic inflammation inhibitor, in patients with advanced solid tumors
    Sun, Yongkun
    Yang, Lin
    Hao, Xuezhi
    Liu, Yutao
    Zhang, Jinwen
    Ning, Zhiqiang
    Shi, Yuankai
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2019, 12 (1)
  • [26] A phase I, dose-escalation study of the Eg5-inhibitor EMD 534085 in patients with advanced solid tumors or lymphoma
    Hollebecque, A.
    Deutsch, E.
    Massard, C.
    Gomez-Roca, C.
    Bahleda, R.
    Ribrag, V.
    Bourgier, C.
    Lazar, V.
    Lacroix, L.
    Gazzah, A.
    Varga, A.
    de Baere, T.
    Beier, F.
    Kroesser, S.
    Trang, K.
    Zenke, F. T.
    Klevesath, M.
    Soria, Jean-Charles
    INVESTIGATIONAL NEW DRUGS, 2013, 31 (06) : 1530 - 1538
  • [27] Phase I dose-escalation study of chiauranib, a novel angiogenic, mitotic, and chronic inflammation inhibitor, in patients with advanced solid tumors
    Yongkun Sun
    Lin Yang
    Xuezhi Hao
    Yutao Liu
    Jinwen Zhang
    Zhiqiang Ning
    Yuankai Shi
    Journal of Hematology & Oncology, 12
  • [28] A phase I, dose-escalation study of the Eg5-inhibitor EMD 534085 in patients with advanced solid tumors or lymphoma
    A. Hollebecque
    E. Deutsch
    C. Massard
    C. Gomez-Roca
    R. Bahleda
    V. Ribrag
    C. Bourgier
    V. Lazar
    L. Lacroix
    A. Gazzah
    A. Varga
    T. de Baere
    F. Beier
    S. Kroesser
    K. Trang
    F. T. Zenke
    M. Klevesath
    Jean-Charles Soria
    Investigational New Drugs, 2013, 31 : 1530 - 1538
  • [29] Phase I study of barasertib (AZD1152), a selective inhibitor of Aurora B kinase, in patients with advanced solid tumors
    Schwartz, Gary K.
    Carvajal, Richard D.
    Midgley, Rachel
    Rodig, Scott J.
    Stockman, Paul K.
    Ataman, Ozlem
    Wilson, David
    Das, Shampa
    Shapiro, Geoffrey I.
    INVESTIGATIONAL NEW DRUGS, 2013, 31 (02) : 370 - 380
  • [30] Phase I dose-escalation study of plitidepsin in combination with bevacizumab in patients with refractory solid tumors
    Aspeslagh, Sandrine
    Awada, Ahmad
    Matos-Pita, Arturo S.
    Aftimos, Philippe
    Bahleda, Ratislav
    Varga, Andrea
    Soria, Jean-Charles
    ANTI-CANCER DRUGS, 2016, 27 (10) : 1021 - 1027
12345